ArticleCEN case reports2026
Tubulointerstitial nephritis with uveitis (TINU) syndrome following COVID-19 vaccination in an elderly patient: a case report.
Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A case of tubulointerstitial nephritis and uveitis (TINU) syndrome in a 70-year-old man following administration of the third dose of the mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine is reported. The patient, who had a history of dyslipidemia, developed anorexia two weeks after vaccination. Laboratory evaluation showed marked elevation of serum creatinine from 0.9 to 2.76 mg/dL, accompanied by proteinuria and elevated tubular injury markers. Renal biopsy confirmed tubulointerstitial nephritis. Shortly thereafter, he developed bilateral ocular pain, and bilateral uveitis was diagnosed on ophthalmological examination. The combination of renal and ocular findings led to the diagnosis of TINU syndrome. Due to progressive renal impairment, the patient received intravenous methylprednisolone pulse therapy (500 mg daily for three days), followed by oral prednisolone (40 mg daily), which was gradually tapered. Both renal function and ocular symptoms improved steadily. This case underscores a rare but important potential adverse event following COVID-19 vaccination, highlighting the need for awareness of immune-mediated complications such as TINU syndrome in the post-vaccination setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.